Alalevonadifloxacin

Alalevonadifloxacin
Clinical data
Trade namesEmrok O
Routes of
administration		Oral
Legal status
Legal status
  • Rx in India
Identifiers
  • (12S)-8-[4-[(2S)-2-Aminopropanoyl]oxypiperidin-1-yl]-7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H26FN3O5
Molar mass431.464 g·mol−1
3D model (JSmol)
  • C[C@H]1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)OC(=O)[C@H](C)N)F)C(=O)O
  • InChI=InChI=1S/C22H26FN3O5/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24/h9-13H,3-8,24H2,1-2H3,(H,28,29)/t11-,12-/m0/s1
  • Key:OUXXDXXQNWKOIF-RYUDHWBXSA-N

Alalevonadifloxacin (trade name Emrok O) is an antibiotic of the fluoroquinolone class.[1] It is a prodrug of levonadifloxacin with increased oral bioavailability.[2] In India, it is approved for the treatment of infections with Gram-positive bacteria.[3]

References

[edit]
  1. ^ Saseedharan S, Dubey D, Singh RK, Zirpe K, Choudhuri AH, Mukherjee DN, et al. (2024). "Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral)". Indian Journal of Medical Microbiology. 47: 100528. doi:10.1016/j.ijmmb.2024.100528. PMID 38228227.
  2. ^ Bhawsar S, Kale R, Deshpande P, Yeole R, Bhagwat S, Patel M (December 2021). "Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection". Bioorganic & Medicinal Chemistry Letters. 54: 128432. doi:10.1016/j.bmcl.2021.128432. PMID 34757217.
  3. ^ "Alalevonadifloxacin". AdisInsight. Springer Nature Switzerland AG.
Stub icon

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Alalevonadifloxacin&oldid=1223595579"